Search Press releases Keywords From To 26 Jun 2024 UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures Read More 14 Jun 2024 Acquisition of own shares Read More 13 Jun 2024 New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels Read More 12 Jun 2024 UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 Read More 10 Jun 2024 Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps Read More 7 Jun 2024 Acquisition of own shares Read More Pagination First page Previous page Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
